Kezar, Everest partner to develop and market zetomipzomib in Asian markets
Everest will obtain exclusive rights to develop and commercialise zetomipzomib in Greater China, South Korea, and other South…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Sep 23
Everest will obtain exclusive rights to develop and commercialise zetomipzomib in Greater China, South Korea, and other South…
21 Sep 23
Under the licensing agreement, RefleXion will develop and commercialise RXM-4768 molecule to direct its SCINTIX biology-guided radiotherapy
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
21 Sep 23
Under the partnership, both parties will discover novel small molecule drugs using Orionis’s Allo-Glue platform for challenging targets…
21 Sep 23
The agreement grants Kyverna Therapeutics access to Oxford Biomedica's LentiVector platform for use with any Kyverna product
20 Sep 23
The primary aim of these collaborations is to advance Merck's research endeavours and generate a range of innovative…
20 Sep 23
Under the agreement, PeptiDream will leverage its PDPS technology to discover, optimise, and develop macrocyclic peptide candidates for…
19 Sep 23
Under the terms of the new agreement, Samsung Biologics will provide drug substance manufacturing for an antibody cancer…
15 Sep 23
The agreement provides Sun Pharma with rights to commercialise Tyvalzi (Sovateltide) for the treatment of acute cerebral ischemic…
14 Sep 23
The Swiss drugmaker will obtain rights to develop and commercialise therapeutic antibodies resulting from the collaboration, while AbCellera…
14 Sep 23
The companies will work together to promote the Devyser laboratory services to support and advance research and development…